Podlesny-Drabiniok Anna, Romero-Molina Carmen, Patel Tulsi, See Wen Yi, Liu Yiyuan, Marcora Edoardo, Goate Alison M
Ronald M. Loeb Center for Alzheimer's Disease, Department of Genetics & Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, New York, NY 10029, USA.
bioRxiv. 2024 Oct 29:2024.10.24.619910. doi: 10.1101/2024.10.24.619910.
Myeloid cells including brain-resident (microglia) and peripheral macrophages play a crucial role in various pathological conditions, including neurodegenerative disorders like Alzheimer's disease (AD). They respond to disruption of tissue homeostasis associated with disease conditions by acquiring various transcriptional and functional states. Experimental investigation of these states is hampered by the lack of tools that enable accessible and robust reprogramming of human macrophages toward Alzheimer's disease-relevant molecular and cellular phenotypes . In this study, we investigated the ability of a cytokine mix, including interleukin-4 (IL4), colony stimulating factor 1 (CSF1/MCSF), interleukin 34 (IL34) and transforming growth factor beta (TGFβ), to induce reprogramming of cultured human THP-1 macrophages. Our results indicate this treatment led to significant transcriptomic changes, driving THP-1 macrophages towards a transcriptional state reminiscent of disease-associated microglia (DAM) and lipid-associated macrophages (LAM) collectively referred to as DLAM. Transcriptome profiling revealed gene expression changes related to oxidative phosphorylation, lysosome function, and lipid metabolism. Single-cell RNA sequencing revealed an increased proportion of DLAM clusters in cytokine mix-treated THP-1 macrophages. Functional assays demonstrated alterations in cell motility, phagocytosis, lysosomal activity, and metabolic and energetic profiles. Our findings provide insights into the cytokine-mediated reprogramming of macrophages towards disease-relevant states, highlighting their role in neurodegenerative diseases and potential for therapeutic development.
包括脑内驻留的(小胶质细胞)和外周巨噬细胞在内的髓样细胞在各种病理状况中发挥着关键作用,包括像阿尔茨海默病(AD)这样的神经退行性疾病。它们通过获得各种转录和功能状态来应对与疾病状况相关的组织稳态破坏。对这些状态的实验研究受到缺乏工具的阻碍,这些工具能够使人类巨噬细胞可及且稳健地重编程为与阿尔茨海默病相关的分子和细胞表型。在本研究中,我们研究了一种细胞因子混合物,包括白细胞介素 - 4(IL4)、集落刺激因子1(CSF1/MCSF)、白细胞介素34(IL34)和转化生长因子β(TGFβ),诱导培养的人THP - 1巨噬细胞重编程的能力。我们的结果表明,这种处理导致了显著的转录组变化,促使THP - 1巨噬细胞趋向于一种转录状态,让人联想到疾病相关的小胶质细胞(DAM)和脂质相关巨噬细胞(LAM),统称为DLAM。转录组分析揭示了与氧化磷酸化、溶酶体功能和脂质代谢相关的基因表达变化。单细胞RNA测序显示,在细胞因子混合物处理的THP - 1巨噬细胞中,DLAM簇的比例增加。功能测定表明细胞运动性、吞噬作用、溶酶体活性以及代谢和能量概况发生了改变。我们的发现为细胞因子介导的巨噬细胞重编程为疾病相关状态提供了见解,突出了它们在神经退行性疾病中的作用以及治疗开发的潜力。